REXAHN PHARMACEUTICALS, INC DEF 14A 6-1-2009

Company

Opus Genetics, Inc.

Filed

April 20, 2009

Period of Report

June 1, 2009

Accession Number

0001140361-09-009978

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →